Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients
127 Greek breast/ovarian cancer families were screened for germline BRCA1/2 mutations by dHPLC followed by direct sequencing. Our results indicated 16 and 5 breast/ovarian cancer families bearing deleterious mutations in the BRCA1 and BRCA2 genes, respectively. Two novel BRCA2 germline mutations (G4...
Gespeichert in:
Veröffentlicht in: | Breast cancer research and treatment 2008-02, Vol.107 (3), p.431-441 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 441 |
---|---|
container_issue | 3 |
container_start_page | 431 |
container_title | Breast cancer research and treatment |
container_volume | 107 |
creator | Konstantopoulou, Irene Rampias, Theodore Ladopoulou, Angela Koutsodontis, George Armaou, Sophia Anagnostopoulos, Theodore Nikolopoulos, George Kamakari, Smaragda Nounesis, George Stylianakis, Antonis Karanikiotis, Charisios Razis, Evangelia Gogas, Helen Keramopoulos, Antonios Gaki, Vassiliki Markopoulos, Christos Skarlos, Dimosthenis Pandis, Nikos Bei, Thalia Arzimanoglou, Iordanis Fountzilas, George Yannoukakos, Drakoulis |
description | 127 Greek breast/ovarian cancer families were screened for germline
BRCA1/2
mutations by dHPLC followed by direct sequencing. Our results indicated 16 and 5 breast/ovarian cancer families bearing deleterious mutations in the
BRCA1
and
BRCA2
genes, respectively. Two novel
BRCA2
germline mutations (G4X and 3783del10) are reported here for the first time. Subsequent compilation of our present findings with previously reported mutation data reveals that in a total of 287 Greek breast/ovarian cancer families, 46 and 13 carry a deleterious mutation in
BRCA1
and
BRCA2
, respectively. It should be noted that two
BRCA1
mutations, 5382insC and G1738R, both located in exon 20, account for 46% of the families found to carry a mutation. Based on our mutation analysis results, we propose here a hierarchical, cost-effective
BRCA1
/2 mutation screening protocol for individuals of Greek ethnic origin. The suggested protocol can impact on the clinical management of breast-ovarian cancer families on a national healthcare system level. |
doi_str_mv | 10.1007/s10549-007-9571-2 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70242598</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1427237191</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-317215b0f02e6376571efa0545205fcd76db7fdb6cfd958063f69a239c5c06a13</originalsourceid><addsrcrecordid>eNqFkdFuFCEUhomxsWv1AbwxxETvaDkwwOJd3dTapImJ0esJw8DutDuwAlPjU_SVZd2xTUyMV_zhfOeHc36EXgE9BUrVWQYqGk2qJFooIOwJWoBQnCgG6ilaUJCKyCWVx-h5zjeUUq2ofoaOQTWCcy4W6P4yOXeLP3xZnQM2of-tGB6nYsoQA847Z0uaxve4_Igz9qeYsbE2TqFgHxPemK3HZeOwNSkNLuV6O1VDM8awxpthvSFpyLe4S87kchbvTBpMqHSwLuFddXSh5BfoyJttdi_n8wR9-3jxdfWJXH--vFqdXxPbcFoIhzqi6KinzEmuZJ3eeVO3IRgV3vZK9p3yfSet77WoG-BeasO4tsJSaYCfoHcH312K3yeXSzsO2brt1gQXp9wqyhom9PK_IGjBhWCygm_-Am_ilEIdomXAGslgySoEB8immHNyvt2lYTTpZwu03WfaHjJt93KfabvveT0bT93o-seOOcQKvJ0Bk21NIdWVDvmBYxRAKWgqxw5crqWwdunxh_9-_ReUq7gt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212462182</pqid></control><display><type>article</type><title>Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Konstantopoulou, Irene ; Rampias, Theodore ; Ladopoulou, Angela ; Koutsodontis, George ; Armaou, Sophia ; Anagnostopoulos, Theodore ; Nikolopoulos, George ; Kamakari, Smaragda ; Nounesis, George ; Stylianakis, Antonis ; Karanikiotis, Charisios ; Razis, Evangelia ; Gogas, Helen ; Keramopoulos, Antonios ; Gaki, Vassiliki ; Markopoulos, Christos ; Skarlos, Dimosthenis ; Pandis, Nikos ; Bei, Thalia ; Arzimanoglou, Iordanis ; Fountzilas, George ; Yannoukakos, Drakoulis</creator><creatorcontrib>Konstantopoulou, Irene ; Rampias, Theodore ; Ladopoulou, Angela ; Koutsodontis, George ; Armaou, Sophia ; Anagnostopoulos, Theodore ; Nikolopoulos, George ; Kamakari, Smaragda ; Nounesis, George ; Stylianakis, Antonis ; Karanikiotis, Charisios ; Razis, Evangelia ; Gogas, Helen ; Keramopoulos, Antonios ; Gaki, Vassiliki ; Markopoulos, Christos ; Skarlos, Dimosthenis ; Pandis, Nikos ; Bei, Thalia ; Arzimanoglou, Iordanis ; Fountzilas, George ; Yannoukakos, Drakoulis</creatorcontrib><description>127 Greek breast/ovarian cancer families were screened for germline
BRCA1/2
mutations by dHPLC followed by direct sequencing. Our results indicated 16 and 5 breast/ovarian cancer families bearing deleterious mutations in the
BRCA1
and
BRCA2
genes, respectively. Two novel
BRCA2
germline mutations (G4X and 3783del10) are reported here for the first time. Subsequent compilation of our present findings with previously reported mutation data reveals that in a total of 287 Greek breast/ovarian cancer families, 46 and 13 carry a deleterious mutation in
BRCA1
and
BRCA2
, respectively. It should be noted that two
BRCA1
mutations, 5382insC and G1738R, both located in exon 20, account for 46% of the families found to carry a mutation. Based on our mutation analysis results, we propose here a hierarchical, cost-effective
BRCA1
/2 mutation screening protocol for individuals of Greek ethnic origin. The suggested protocol can impact on the clinical management of breast-ovarian cancer families on a national healthcare system level.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-007-9571-2</identifier><identifier>PMID: 17453335</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Biological and medical sciences ; Breast cancer ; Breast Neoplasms - genetics ; Cancer research ; Cost-Benefit Analysis ; Epidemiology ; Female ; Female genital diseases ; Genes ; Genes, BRCA1 ; Genes, BRCA2 ; Greece ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Medicine ; Medicine & Public Health ; Minority & ethnic groups ; Mutation ; Oncology ; Ovarian cancer ; Ovarian Neoplasms - genetics ; Population genetics ; Tumors</subject><ispartof>Breast cancer research and treatment, 2008-02, Vol.107 (3), p.431-441</ispartof><rights>Springer Science+Business Media, LLC 2007</rights><rights>2008 INIST-CNRS</rights><rights>Springer Science+Business Media, LLC. 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-317215b0f02e6376571efa0545205fcd76db7fdb6cfd958063f69a239c5c06a13</citedby><cites>FETCH-LOGICAL-c430t-317215b0f02e6376571efa0545205fcd76db7fdb6cfd958063f69a239c5c06a13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-007-9571-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-007-9571-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20117714$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17453335$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Konstantopoulou, Irene</creatorcontrib><creatorcontrib>Rampias, Theodore</creatorcontrib><creatorcontrib>Ladopoulou, Angela</creatorcontrib><creatorcontrib>Koutsodontis, George</creatorcontrib><creatorcontrib>Armaou, Sophia</creatorcontrib><creatorcontrib>Anagnostopoulos, Theodore</creatorcontrib><creatorcontrib>Nikolopoulos, George</creatorcontrib><creatorcontrib>Kamakari, Smaragda</creatorcontrib><creatorcontrib>Nounesis, George</creatorcontrib><creatorcontrib>Stylianakis, Antonis</creatorcontrib><creatorcontrib>Karanikiotis, Charisios</creatorcontrib><creatorcontrib>Razis, Evangelia</creatorcontrib><creatorcontrib>Gogas, Helen</creatorcontrib><creatorcontrib>Keramopoulos, Antonios</creatorcontrib><creatorcontrib>Gaki, Vassiliki</creatorcontrib><creatorcontrib>Markopoulos, Christos</creatorcontrib><creatorcontrib>Skarlos, Dimosthenis</creatorcontrib><creatorcontrib>Pandis, Nikos</creatorcontrib><creatorcontrib>Bei, Thalia</creatorcontrib><creatorcontrib>Arzimanoglou, Iordanis</creatorcontrib><creatorcontrib>Fountzilas, George</creatorcontrib><creatorcontrib>Yannoukakos, Drakoulis</creatorcontrib><title>Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>127 Greek breast/ovarian cancer families were screened for germline
BRCA1/2
mutations by dHPLC followed by direct sequencing. Our results indicated 16 and 5 breast/ovarian cancer families bearing deleterious mutations in the
BRCA1
and
BRCA2
genes, respectively. Two novel
BRCA2
germline mutations (G4X and 3783del10) are reported here for the first time. Subsequent compilation of our present findings with previously reported mutation data reveals that in a total of 287 Greek breast/ovarian cancer families, 46 and 13 carry a deleterious mutation in
BRCA1
and
BRCA2
, respectively. It should be noted that two
BRCA1
mutations, 5382insC and G1738R, both located in exon 20, account for 46% of the families found to carry a mutation. Based on our mutation analysis results, we propose here a hierarchical, cost-effective
BRCA1
/2 mutation screening protocol for individuals of Greek ethnic origin. The suggested protocol can impact on the clinical management of breast-ovarian cancer families on a national healthcare system level.</description><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - genetics</subject><subject>Cancer research</subject><subject>Cost-Benefit Analysis</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Genes</subject><subject>Genes, BRCA1</subject><subject>Genes, BRCA2</subject><subject>Greece</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Minority & ethnic groups</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Population genetics</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkdFuFCEUhomxsWv1AbwxxETvaDkwwOJd3dTapImJ0esJw8DutDuwAlPjU_SVZd2xTUyMV_zhfOeHc36EXgE9BUrVWQYqGk2qJFooIOwJWoBQnCgG6ilaUJCKyCWVx-h5zjeUUq2ofoaOQTWCcy4W6P4yOXeLP3xZnQM2of-tGB6nYsoQA847Z0uaxve4_Igz9qeYsbE2TqFgHxPemK3HZeOwNSkNLuV6O1VDM8awxpthvSFpyLe4S87kchbvTBpMqHSwLuFddXSh5BfoyJttdi_n8wR9-3jxdfWJXH--vFqdXxPbcFoIhzqi6KinzEmuZJ3eeVO3IRgV3vZK9p3yfSet77WoG-BeasO4tsJSaYCfoHcH312K3yeXSzsO2brt1gQXp9wqyhom9PK_IGjBhWCygm_-Am_ilEIdomXAGslgySoEB8immHNyvt2lYTTpZwu03WfaHjJt93KfabvveT0bT93o-seOOcQKvJ0Bk21NIdWVDvmBYxRAKWgqxw5crqWwdunxh_9-_ReUq7gt</recordid><startdate>20080201</startdate><enddate>20080201</enddate><creator>Konstantopoulou, Irene</creator><creator>Rampias, Theodore</creator><creator>Ladopoulou, Angela</creator><creator>Koutsodontis, George</creator><creator>Armaou, Sophia</creator><creator>Anagnostopoulos, Theodore</creator><creator>Nikolopoulos, George</creator><creator>Kamakari, Smaragda</creator><creator>Nounesis, George</creator><creator>Stylianakis, Antonis</creator><creator>Karanikiotis, Charisios</creator><creator>Razis, Evangelia</creator><creator>Gogas, Helen</creator><creator>Keramopoulos, Antonios</creator><creator>Gaki, Vassiliki</creator><creator>Markopoulos, Christos</creator><creator>Skarlos, Dimosthenis</creator><creator>Pandis, Nikos</creator><creator>Bei, Thalia</creator><creator>Arzimanoglou, Iordanis</creator><creator>Fountzilas, George</creator><creator>Yannoukakos, Drakoulis</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20080201</creationdate><title>Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients</title><author>Konstantopoulou, Irene ; Rampias, Theodore ; Ladopoulou, Angela ; Koutsodontis, George ; Armaou, Sophia ; Anagnostopoulos, Theodore ; Nikolopoulos, George ; Kamakari, Smaragda ; Nounesis, George ; Stylianakis, Antonis ; Karanikiotis, Charisios ; Razis, Evangelia ; Gogas, Helen ; Keramopoulos, Antonios ; Gaki, Vassiliki ; Markopoulos, Christos ; Skarlos, Dimosthenis ; Pandis, Nikos ; Bei, Thalia ; Arzimanoglou, Iordanis ; Fountzilas, George ; Yannoukakos, Drakoulis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-317215b0f02e6376571efa0545205fcd76db7fdb6cfd958063f69a239c5c06a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - genetics</topic><topic>Cancer research</topic><topic>Cost-Benefit Analysis</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Genes</topic><topic>Genes, BRCA1</topic><topic>Genes, BRCA2</topic><topic>Greece</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Minority & ethnic groups</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Population genetics</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Konstantopoulou, Irene</creatorcontrib><creatorcontrib>Rampias, Theodore</creatorcontrib><creatorcontrib>Ladopoulou, Angela</creatorcontrib><creatorcontrib>Koutsodontis, George</creatorcontrib><creatorcontrib>Armaou, Sophia</creatorcontrib><creatorcontrib>Anagnostopoulos, Theodore</creatorcontrib><creatorcontrib>Nikolopoulos, George</creatorcontrib><creatorcontrib>Kamakari, Smaragda</creatorcontrib><creatorcontrib>Nounesis, George</creatorcontrib><creatorcontrib>Stylianakis, Antonis</creatorcontrib><creatorcontrib>Karanikiotis, Charisios</creatorcontrib><creatorcontrib>Razis, Evangelia</creatorcontrib><creatorcontrib>Gogas, Helen</creatorcontrib><creatorcontrib>Keramopoulos, Antonios</creatorcontrib><creatorcontrib>Gaki, Vassiliki</creatorcontrib><creatorcontrib>Markopoulos, Christos</creatorcontrib><creatorcontrib>Skarlos, Dimosthenis</creatorcontrib><creatorcontrib>Pandis, Nikos</creatorcontrib><creatorcontrib>Bei, Thalia</creatorcontrib><creatorcontrib>Arzimanoglou, Iordanis</creatorcontrib><creatorcontrib>Fountzilas, George</creatorcontrib><creatorcontrib>Yannoukakos, Drakoulis</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Konstantopoulou, Irene</au><au>Rampias, Theodore</au><au>Ladopoulou, Angela</au><au>Koutsodontis, George</au><au>Armaou, Sophia</au><au>Anagnostopoulos, Theodore</au><au>Nikolopoulos, George</au><au>Kamakari, Smaragda</au><au>Nounesis, George</au><au>Stylianakis, Antonis</au><au>Karanikiotis, Charisios</au><au>Razis, Evangelia</au><au>Gogas, Helen</au><au>Keramopoulos, Antonios</au><au>Gaki, Vassiliki</au><au>Markopoulos, Christos</au><au>Skarlos, Dimosthenis</au><au>Pandis, Nikos</au><au>Bei, Thalia</au><au>Arzimanoglou, Iordanis</au><au>Fountzilas, George</au><au>Yannoukakos, Drakoulis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2008-02-01</date><risdate>2008</risdate><volume>107</volume><issue>3</issue><spage>431</spage><epage>441</epage><pages>431-441</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>127 Greek breast/ovarian cancer families were screened for germline
BRCA1/2
mutations by dHPLC followed by direct sequencing. Our results indicated 16 and 5 breast/ovarian cancer families bearing deleterious mutations in the
BRCA1
and
BRCA2
genes, respectively. Two novel
BRCA2
germline mutations (G4X and 3783del10) are reported here for the first time. Subsequent compilation of our present findings with previously reported mutation data reveals that in a total of 287 Greek breast/ovarian cancer families, 46 and 13 carry a deleterious mutation in
BRCA1
and
BRCA2
, respectively. It should be noted that two
BRCA1
mutations, 5382insC and G1738R, both located in exon 20, account for 46% of the families found to carry a mutation. Based on our mutation analysis results, we propose here a hierarchical, cost-effective
BRCA1
/2 mutation screening protocol for individuals of Greek ethnic origin. The suggested protocol can impact on the clinical management of breast-ovarian cancer families on a national healthcare system level.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>17453335</pmid><doi>10.1007/s10549-007-9571-2</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0167-6806 |
ispartof | Breast cancer research and treatment, 2008-02, Vol.107 (3), p.431-441 |
issn | 0167-6806 1573-7217 |
language | eng |
recordid | cdi_proquest_miscellaneous_70242598 |
source | MEDLINE; Springer Nature - Complete Springer Journals |
subjects | Biological and medical sciences Breast cancer Breast Neoplasms - genetics Cancer research Cost-Benefit Analysis Epidemiology Female Female genital diseases Genes Genes, BRCA1 Genes, BRCA2 Greece Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Medicine Medicine & Public Health Minority & ethnic groups Mutation Oncology Ovarian cancer Ovarian Neoplasms - genetics Population genetics Tumors |
title | Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T19%3A43%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Greek%20BRCA1%20and%20BRCA2%20mutation%20spectrum:%20two%20BRCA1%20mutations%20account%20for%20half%20the%20carriers%20found%20among%20high-risk%20breast/ovarian%20cancer%20patients&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Konstantopoulou,%20Irene&rft.date=2008-02-01&rft.volume=107&rft.issue=3&rft.spage=431&rft.epage=441&rft.pages=431-441&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-007-9571-2&rft_dat=%3Cproquest_cross%3E1427237191%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212462182&rft_id=info:pmid/17453335&rfr_iscdi=true |